This session will showcase Wake Forest University School of Medicine’s commitment to advancing imaging science as a cornerstone of precision medicine. The panel brings together leading experts in addiction PET imaging, Alzheimer’s disease PET imaging, clinical PET with theranostics, and PET imaging in radiation cohorts to explore how cutting-edge molecular imaging is transforming basic, translational, and clinical research, as well as patient care.

Attendees will gain insights into emerging radiotracers, quantitative imaging biomarkers, novel imaging platforms, and theranostic strategies that reveal key molecular mechanisms and enable personalized treatment planning.

The discussion will emphasize how PET technologies are driving earlier diagnosis, guiding therapeutic decisions, and improving outcomes across diverse clinical settings, while identifying opportunities for collaboration to integrate these innovations into routine practice. 

Agenda

Time Activity
1:00 pm - 1:50 pm Panel Discussion
1:50 pm - 2:05 pm Q&A
2:05 pm - 2:30 pm Reception

Speakers

Associate Professor, Radiology/Neuroradiology

Dr.  Benayoun is a dual-boarded Associate Professor of Neuroradiology and Nuclear Medicine at Atrium Health Wake Forest Medical Center. He completed his nuclear medicine training at Emory University Hospital and his neuroradiology fellowship at Massachusetts General Hospital. He obtained his MD and PhD from the University of Chicago. He is currently the Co-Chief of Nuclear Medicine and the Medical Director of MRI and Nuclear Medicine and PET. Dr. Benayoun has a strong interest in molecular neuroimaging and neurotheragnostics. He has been instrumental in building up the Lu-177 PSMA service line at Atrium Health Wake Forest and helping to advance clinical trials for theragnostics at Wake Forest University School of Medicine. 

Professor of Pathology/Comparative Medicine; Director, Wake Forest Primate Research Center

Dr.  Cline is an experienced researcher with over 30 years of continuous extramural funding, focused on naturally-occurring models of cancer in nonhuman primates, hormone-dependent cancers, development of novel targeted cancer therapeutic strategies, and delayed effects of radiation exposure. He has chaired a number of NIH study sections and review panels and has served on advisory committees for NASA and the National Academies for Science, Engineering, and Medicine. 

Director of Alzheimer’s Disease Research Center and Professor of Internal Medicine

Dr. Craft is the founding Director of the Wake Forest Alzheimer’s Disease Research Center (ADRC), co-director of Stitch Center for Healthy Aging and Alzheimer’s Prevention. She is a nationally recognized leader in translational research on Alzheimer’s disease and related dementias. Her work focuses on metabolic risk factors, particularly insulin resistance, and she has pioneered studies demonstrating that intranasal insulin (INI) can improve memory and modulate key metabolic and inflammatory pathways in individuals with mild cognitive impairment and early AD. Dr. Craft has led multiple NIH-funded clinical trials targeting insulin signaling deficits through INI, insulin sensitizers, and dietary interventions, and her research has been continuously supported by NIH for over 25 years. She is a recipient of the NIH MERIT Award and the Alzheimer’s Association Zenith Award and serves on national advisory boards, including the NIA Board of Scientific Counselors. Her recent first-in-human PET study of INI delivery underscores her commitment to biomarker-driven approaches and precision medicine for Alzheimer’s. 

Professor, Department of Translational Neuroscience,  Wake Forest University School of Medicine

Dr. Czoty is a behavioral pharmacologist and neuroscientist with 30+ years of experience conducting research using nonhuman primate models of substance use disorders. His research uses behavioral procedures, including drug self-administration and non-invasive brain imaging, including MRI and PET, to characterize the effects of long-term drug use on the brain. Other major research areas are characterization of behavioral, neurobiological and environmental factors that predispose individuals to substance abuse and development of novel medications. He has been heavily involved in recruiting, educating and training graduate students during his 23 years at the Wake Forest University School of Medicine, including serving currently as Director of the Neuroscience graduate programs.

Associate Professor of Radiology

Dr. Solingapuram Sai is an Associate Professor of Radiology, Director of PET imaging center, and the inaugural Deans Research Scholar at the Wake Forest University School of Medicine. His work focuses on developing , evaluating, and translating novel first-in-class PET radiotracers for neurological disorders; his lab is fully funded and published around 85 publications in several high-impact scientific journals. Trained as a radiochemist, Dr. Sai brings extensive experience in automation, validation, and GMP/FDA-compliant protocols to translate radiotracers from preclinical to clinical settings, including microtubule, insulin, and nicotine PET. He also serves on several national and international molecular imaging boards, contributing to training, education, and scientific research initiatives.